Zicronapine

Zicronapine (, previously known as Lu 31-130) is an atypical antipsychotic medication currently under development by H. Lundbeck A/S. In phase II studies zicronapine did show statistical significant separation from placebo and very convincing efficacy and safety data when compared to olanzapine.

Zicronapine exhibits monoaminergic activity and has a multi-receptorial profile. In vitro and in vivo it has shown potent antagonistic effects at dopamine D1, D2 and serotonin 5HT2A receptors.